[Vpcomorbidities-subgroup] About using a multi-scale mortality model in the ensemble

Tue Dec 22 01:42:46 PST 2020

Thanks Filippo,

Your example is nice since you include a functional form that can be
reproduced fairly easily by plugging in the coefficients. However, it seems
I will have to wait until you upload the paper to biorxiv so I can better
understand what you are showing and if I can reuse it. Allow me to explain
my thoughts.

Your plot indicates that after 80 days only about 10% of the
population have a viral load larger than theta. Also you indicate that your
arbitrary death definition is viral load theta above 1000 in day 30.

What I am looking for is a little bit different, What I want is the
probability of death as a function on time. For example, I assume the
probability at the day of infection will be zero since the virus did not
spread in the body and the probability will then gradually rise as days
pass until a peak and then drop again and will be close to zero after
several weeks when subjects recover and can no longer die from the disease.

The question is if it is possible to derive such a function from your data?
- and if yes, exactly how?

When integrating models, many time the issue is that the models presented
in the publication need some manipulation, Many times this manipulation is
trivial, yet many other times it requires some transformation and deep
comprehension of the details and sometimes the model is unusable for some
purposes because it calculates something different. This is what I am
trying to figure out in this case and I need more information.

Unless you can help extract the function I am looking for before
publication, I will have to wait for the preprint and will be happy to
continue this public conversation on this thread.

                Jacob

On Mon, Dec 21, 2020 at 4:46 AM Filippo Castiglione <
filippo.castiglione at gmail.com> wrote:

> Dear Jacob, please see attachment as a reply to your mail.
>
> I could parametrise the “model” further with respect to patient’s age but
> I though the reply in attachment might be already ok for your purpose. You
> tell me.
>
> As for the permission to use it for commercial purposes I can declare no
> restrictions (so far ;).
>
> Best wishes
> Fil
>
>
>
> > On 20 Dec 2020, at 23:53, Jacob Barhak <jacob.barhak at gmail.com> wrote:
> >
> > Well Filippo,
> >
> > Since the discussion is relevant to the comorbidities subgroup and to
> the integration subgroup, you will find both mailing lists CCd. I suggest
> we try to keep this discussion public and merge it with the working group
> activities. I believe others will find interest in this discussion as it
> may be relevant to their activities. I am copying the entire email
> conversation below.
> >
> > To your question about if I am suggesting to use your whole model to
> simulate mortality?
> >
> > The answer is: almost.
> >
> > Your model has important utility towards calculating mortality. However,
> I only need your output at this point. What I am asking for is the output
> of your model as a function. Something like:
> >
> > probability_death  = f (days since infection)
> >
> > And at this initial point f does not have to be in functional form. It
> is enough for simulation purposes to have an x,y table where x is from 0 to
> 60 in days for each day and the associated mortality probability.
> >
> > And it is ok if you give me several assumptions with different cutoff
> values in your model.
> >
> > The ensemble model will balance those assumptions with other models and
> assumptions. If the assumptions do not merge well with other
> assumptions/models, the ensemble model should assign them less influence.
> >
> > So if you can use the model you showed at the webinar to derive
> different mortality functions and send those to me as a table - it will be
> great.
> >
> > However, please also make sure you give me permission to use those for
> commercial purposes - I do intend to monetize my technology and therefore
> avoid using information that has restrictions. I did declare a conflict of
> interest and I am making it public. However, I hope we can still
> collaborate.
> >
> >                Jacob
> >
> > --
> > Jacob Barhak Ph.D.
> > Sole Proprietor, Software Developer, and Computational Disease Modeler
> > https://sites.google.com/view/jacob-barhak/home
> >
> >
> >
> >
> > On Sun, Dec 20, 2020 at 2:40 AM Filippo Castiglione <
> filippo.castiglione at gmail.com> wrote:
> > Dear Jacob, sure this conversation is open.
> >
> > Coming back to the mortality model question are you suggesting to use my
> whole model to simulate mortality? If yes, then It is possible at the
> condition that we define when the simulation should stop for “death”.
> >
> >
> > Best
> >
> > --- Filippo (@iPhone)
> >
> >> On 19 Dec 2020, at 21:48, Jacob Barhak <jacob.barhak at gmail.com> wrote:
> >>
> >> 
> >> Thanks Filippo,
> >>
> >> Yes, you are correct, the mortality models are not accurate. All models
> are assumptions - none of them are really accurate. The Reference Model was
> built to figure out how well they perform and provide a reference modelers
> can compare their models to.
> >>
> >> Your suggestions make sense and in fact I already have several
> mortality models plugged into my model. Yet those are simplified and not
> multi scale models.
> >>
> >> The value in your approach is that it makes this multi scale - if you
> would plug your model in the ensemble and the ensemble will prefer it to
> other models - this will give the multi scale model validation of sorts.
> >>
> >> And with your permission, I would like to add this conversation to the
> co-morbidities mailing list that I plan to create or to the integration
> mailing list in the integration working group portal:
> >> https://lists.simtk.org/pipermail/vp-integration-subgroup/
> >>
> >> Hopefully you are ok with making this conversation public and part of
> the working group discussions.
> >>
> >>              Jacob
> >>
> >>
> >>
> >> On Sat, Dec 19, 2020 at 2:48 AM Filippo Castiglione <
> f.castiglione at iac.cnr.it> wrote:
> >> Hi Jacob.
> >>
> >> The only thing I feel to suggest is to use survival curves of covid
> patients. I don’t know if you can recall them somewhere from clinical
> available data (e.g.,
> https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-09721-2).
>
> >> You might be interested in age-related of such curves (Kaplan-Meier
> curves plot 1-P(death)).
> >>
> >> I might calculated them starting from my simulations but they would be
> inaccurate because based on an artificial definition of “death” that, of
> course, I don’t have. Let me know if you want to try it anyway but I
> suggest to look for them around.
> >>
> >> Another very simple stylised model of mortality would be to use a
> reverse sigmoid function to represent the upside-down sigmoid shape (long
> right tail) of a generic Kaplan-Meier plot centred around the "typical
> value” time of death. For instance such t could be in the range 7-15 days,
> for instance, 1-0.2/(1+exp(7-x)) where 1-0.2 is the asymptotic value and 7
> is the typical death t.
> >>
> >> Let me know if I expressed my thoughts clearly.
> >>
> >> All the best
> >> Fil
> >>
> >> > On 18 Dec 2020, at 18:38, Jacob Barhak <jacob.barhak at gmail.com>
> wrote:
> >> >
> >> > Hi Filippo,
> >> >
> >> > Following your talk at the webinar yesterday, you may recall that I
> was interested in a mortality model based on time.
> >> >
> >> > I wanted to communicate with you about it to see what is possible.
> >> >
> >> > I am looking for models to plug into my ensemble model. You can see
> quickly how it looks in this video - I am pointing at the point where I
> show some ensemble results:
> >> > https://youtu.be/aTB8-XEZheU?t=1000
> >> >
> >> > I am actively looking for several types of models to integrate into
> my model. One of the models can be mortality models.  Currently I use two
> different models for mortality - one of overall risk and one for death. I
> do not have a probability of death per day from infection and looking at
> your plots I figured you may have something - even at a level of an
> assumption.
> >> >
> >> > Do you think it is possible to get such models from you and if so,
> under what terms?
> >> >
> >> > Hopefully you can help.
> >> >
> >> >                Jacob
> >> >
> >> >
> >> >
> >> > On Mon, Dec 7, 2020 at 7:57 AM Jacob Barhak <jacob.barhak at gmail.com>
> wrote:
> >> > Ok Filippo,
> >> >
> >> > You are in a similar situation to many others.
> >> >
> >> > Your situation is very common and well understood.
> >> >
> >> >         Jacob
> >> >
> >> > On Mon, Dec 7, 2020, 02:37 Filippo Castiglione <
> f.castiglione at iac.cnr.it> wrote:
> >> > Dear Jacob, sorry for the late response.
> >> >
> >> > I recently realised I had subscribed to too many groups to be
> practically able to follow, so opted out from many of them included the
> comorbidity. I asked Bruce to update the groups’ lists.
> >> >
> >> > All the best
> >> > Fil
> >> >
> >> > > On 6 Dec 2020, at 06:23, Jacob Barhak <jacob.barhak at gmail.com>
> wrote:
> >> > >
> >> > > Hi Filippo,
> >> > >
> >> > > You were listed as interested in comorbidities within the viral
> pandemic working group. I am going over each member personally to see why
> they signed up.
> >> > >
> >> > > I looked at your web site:
> >> > >
> >> > > https://www.iac.cnr.it/~filippo/about-me.html
> >> > >
> >> > > Your interest in co-morbidities is visible directly from what you
> state in your web site:
> >> > > "particular interest in the immune system and related pathologies"
> >> > >
> >> > > I wonder why you did not respond to my email to step up and co-lead
> this sub-working group. After all you have many publications and experience
> in leadership.
> >> > >
> >> > > Hopefully my personal email will get a response.
> >> > >
> >> > >              Jacob
> >> > >
> >> > > --
> >> > > Jacob Barhak Ph.D.
> >> > > https://sites.google.com/view/jacob-barhak/home
> >> > >
> >> >
> >>
>
>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://lists.simtk.org/pipermail/vpcomorbidities-subgroup/attachments/20201222/2332bfe4/attachment.html>